The point that is being missed here is that it doesn't really matter who profits if Advent is sold. Advent is likely a huge unnecessary complication and distraction for NWBO to have any capital or operational ownership of. Advent is just a necessary part of the puzzle for regulatory approval and for DC-Vax to be a success. It's even less of a point if Flaskworks is successful because then NWBO shareholders will own the whole process, end to end and be likely receiving compensation in some fashion for the use of the technology. I don't understand the neverending argument on this. The only thing we should be worried about is successful TLD which we all know that worrying is "needless" ;)
That’s fine, but we become more attractive to Merck. I don’t think Merck would pay in excess of $20B or anywhere close to that for Nwbo if they don’t have in-house manufacturing expertise to go along. How much would it cost them to buy CRL as opposed to Advent? At least a few billion more. They would rather use that savings to pay extra premium towards the purchase of NWBO and some towards building their own Advent facility in the US. And who benefits from that?
News 
Market Data 
Discover 
AI
